Department of Nursing, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Department of Nursing, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
BMJ Open. 2024 May 31;14(5):e082709. doi: 10.1136/bmjopen-2023-082709.
INTRODUCTION: Prostate cancer is the most common malignant disease within the male genitourinary system. Advances in cancer screening and treatment have significantly ameliorated the survival rates of patients with prostate cancer. Nonetheless, prostate cancer survivors report various degrees of cancer-related symptoms. These symptoms cause physiological and psychological suffering, leading to a deterioration of quality of life. Web-based interventions may facilitate the management of symptoms due to their flexibility, accessibility and convenience. However, the efficacy of web-based interventions in reducing symptom burden remains to be confirmed. Consequently, this systematic review and meta-analysis aims to comprehensively synthesise existing evidence, evaluate the effectiveness of web-based interventions in reducing symptom burden among patients and furnish a reference for clinical practice. METHODS AND ANALYSIS: This protocol strictly adheres to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocol guidelines. We will comprehensively search six databases (PubMed, Web of Science, Cochrane, Embase, CINAHL and PsycINFO) from their inception to March 2024 in order to identify clinical trials on the efficacy of web-based interventions for prostate cancer survivors. Two reviewers will independently conduct study selection, data extraction and quality assessment. The risk bias of included studies will be assessed using the Cochrane Risk of Bias Tool for randomised trials 2.0, and the strength of evidence will be assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) guideline. Meta-analysis will be performed using STATA V.16.0, and the effect size will be calculated using the standardised mean difference and its 95% CI. Heterogeneity will be assessed using Cochran's Q statics and inconsistency will be measured using the I statistics. Potential sources of bias will be evaluated. ETHICS AND DISSEMINATION: Ethics approval is not required for this review as no human participants will be involved. The results will be disseminated via a peer-reviewed journal or an academic conference. PROSPERO REGISTRATION NUMBER: CRD42023457718.
简介：前列腺癌是男性泌尿生殖系统中最常见的恶性疾病。癌症筛查和治疗的进步显著提高了前列腺癌患者的生存率。然而，前列腺癌幸存者报告了不同程度的与癌症相关的症状。这些症状导致生理和心理上的痛苦，导致生活质量下降。基于网络的干预措施具有灵活性、可及性和便利性，可能有助于管理症状。然而，基于网络的干预措施在减轻症状负担方面的疗效仍有待证实。因此，本系统评价和荟萃分析旨在全面综合现有证据，评估基于网络的干预措施在减轻前列腺癌幸存者症状负担方面的有效性，并为临床实践提供参考。 方法和分析：本方案严格遵循系统评价和荟萃分析报告的首选条目（PRISMA）协议。我们将全面搜索六个数据库（PubMed、Web of Science、Cochrane、Embase、CINAHL 和 PsycINFO），从它们的建立到 2024 年 3 月，以确定关于基于网络的干预措施对前列腺癌幸存者疗效的临床试验。两名评审员将独立进行研究选择、数据提取和质量评估。使用 Cochrane 随机试验偏倚风险工具 2.0 评估纳入研究的风险偏倚，并使用推荐评估、制定和评估（GRADE）指南评估证据强度。使用 STATA V.16.0 进行荟萃分析，使用标准化均数差及其 95%置信区间计算效应量。使用 Cochran's Q 统计量评估异质性，使用 I 统计量测量不一致性。将评估潜在的偏倚来源。 伦理和传播：由于本综述不涉及人类参与者，因此不需要伦理批准。结果将通过同行评议的期刊或学术会议传播。 PROSPERO 注册号：CRD42023457718。
Cochrane Database Syst Rev. 2022-2-1
J Med Internet Res. 2023-1-19
Asia Pac J Oncol Nurs. 2021-10-4
Zotero 插件